Quantbot Technologies LP Makes New Investment in Hologic, Inc. $HOLX

Key Points

• Quantbot Technologies LP has acquired a new stake in Hologic, Inc. (NASDAQ: HOLX) by purchasing 113,406 shares worth approximately $7 million, now owning about 0.05% of the company.
• Several hedge funds, including Victory Capital Management and Nuance Investments, have significantly increased their holdings in Hologic, with over 94% of the stock currently owned by institutional investors.
• Analysts have mixed ratings on Hologic, with Citigroup upgrading the stock to a "buy" and setting a target price of $80, while the average analyst target price stands at $78.

Quantbot Technologies LP bought a new position in Hologic, Inc. (NASDAQ:HOLX - Free Report) in the first quarter, according to the company in its most recent disclosure with the SEC. The fund bought 113,406 shares of the medical equipment provider's stock, valued at approximately $7,005,000. Quantbot Technologies LP owned 0.05% of Hologic at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in HOLX. CANADA LIFE ASSURANCE Co grew its position in Hologic by 4.8% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 276,408 shares of the medical equipment provider's stock worth $19,912,000 after purchasing an additional 12,695 shares during the period. Commerce Bank boosted its stake in shares of Hologic by 2.5% during the 4th quarter. Commerce Bank now owns 12,243 shares of the medical equipment provider's stock worth $883,000 after acquiring an additional 294 shares during the last quarter. Forum Financial Management LP purchased a new position in shares of Hologic during the 4th quarter worth $324,000. First Trust Advisors LP boosted its stake in shares of Hologic by 75.5% during the 4th quarter. First Trust Advisors LP now owns 308,979 shares of the medical equipment provider's stock worth $22,274,000 after acquiring an additional 132,943 shares during the last quarter. Finally, Dimensional Fund Advisors LP boosted its stake in shares of Hologic by 6.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 2,625,290 shares of the medical equipment provider's stock worth $189,264,000 after acquiring an additional 169,427 shares during the last quarter. Institutional investors own 94.73% of the company's stock.

Analyst Upgrades and Downgrades

HOLX has been the topic of several analyst reports. Needham & Company LLC reiterated a "hold" rating on shares of Hologic in a research note on Tuesday, May 27th. Stephens dropped their price target on shares of Hologic from $77.00 to $70.00 and set an "overweight" rating on the stock in a research note on Tuesday, May 13th. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and lifted their price target for the stock from $60.00 to $80.00 in a research note on Wednesday, July 9th. Wall Street Zen upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Mizuho set a $75.00 target price on shares of Hologic in a research note on Thursday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

Hologic Price Performance

Shares of HOLX traded up $1.09 during trading hours on Friday, reaching $68.26. 1,545,907 shares of the stock traded hands, compared to its average volume of 1,851,908. The company has a current ratio of 3.55, a quick ratio of 2.81 and a debt-to-equity ratio of 0.52. Hologic, Inc. has a 52-week low of $51.90 and a 52-week high of $84.39. The company's 50-day moving average price is $65.90 and its two-hundred day moving average price is $62.42. The company has a market cap of $15.18 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 2.48 and a beta of 0.49.

Hologic (NASDAQ:HOLX - Get Free Report) last released its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 earnings per share for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The company had revenue of $1.02 billion for the quarter, compared to analysts' expectations of $1.01 billion. Hologic had a net margin of 13.79% and a return on equity of 19.69%. Hologic's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the previous year, the company earned $1.06 EPS. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, analysts anticipate that Hologic, Inc. will post 4.28 earnings per share for the current year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.